402 related articles for article (PubMed ID: 15188623)
1. [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Inoue T; Ohyama C; Horikawa Y; Togashi H; Matsuura S; Tsuchiya N; Satoh S; Sato K; Habuchi T; Saito S; Hoshi S; Arai Y; Kato T
Hinyokika Kiyo; 2004 Apr; 50(4):273-7. PubMed ID: 15188623
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
3. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
7. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
9. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Lehmann J; Retz M; Steiner G; Albers P; Jaeger E; Knuth A; Lippert C; Koser M; Stockamp K; Otto C; Melchior H; Fassmann C; Potratz C; Loch T; Derigs HG; Becker T; Kälble T; Piechota HJ; Hertle L; Weinknecht S; Weissbach L; Al-Mwalad M; Hamza A; Henss H; Brkovic D; Pomer S; Roloff J; Walz P; Muschter R; Tunn U; Winter E; Bub P; Kaldenbach U; Roth S; Brauers A; Jakse G; Richter AE; Wirth M; Hartlapp J; Van Ahlen H; Stöckle M
Urologe A; 2003 Aug; 42(8):1074-86. PubMed ID: 14513232
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Artz A; Stadler WM; Vogelzang NJ; Zimmerman T; Ryan C
Am J Clin Oncol; 2005 Apr; 28(2):109-13. PubMed ID: 15803001
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience.
Dorff TB; Tsao-Wei D; Miranda G; Skinner DG; Stein JP; Quinn DI
World J Urol; 2009 Feb; 27(1):39-44. PubMed ID: 19020886
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
von der Maase H; Sengelov L; Roberts JT; Ricci S; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
J Clin Oncol; 2005 Jul; 23(21):4602-8. PubMed ID: 16034041
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Lee Y; Kim YS; Hong B; Cho YM; Lee JL
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Hoshi S; Ohyama C; Ono K; Takeda A; Yamashita S; Yamato T; Itoh A; Satoh M; Saito S; Okada Y; Sohma F; Arai Y
Int J Clin Oncol; 2004 Apr; 9(2):125-9. PubMed ID: 15108045
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
17. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
[TBL] [Abstract][Full Text] [Related]
18. [Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Inoue T; Obara T; Saito M; Kumazawa T; Narita S; Horikawa Y; Yuasa T; Tsuchiya N; Satoh S; Habuchi T
Hinyokika Kiyo; 2008 Sep; 54(9):581-5. PubMed ID: 18975570
[TBL] [Abstract][Full Text] [Related]
19. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Bamias A; Efstathiou E; Moulopoulos LA; Gika D; Hamilos G; Zorzou MP; Kakoyiannis C; Kastritis E; Bozas G; Papadimitriou C; Dimopoulos MA
Ann Oncol; 2005 Feb; 16(2):307-13. PubMed ID: 15668289
[TBL] [Abstract][Full Text] [Related]
20. The present and future of combination chemotherapy in bladder cancer.
Culine S
Semin Oncol; 2002 Jun; 29(3 Suppl 9):32-9. PubMed ID: 12094336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
